- < General Internal Medicine
First-line cadonilimab plus chemotherapy in HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma: a randomized, double-blind, phase 3 trial
By sjmartinez • January 23, 2025
Shen L, Zhang Y, Li Z, Zhang X, Gao X, Liu B, Wang Y, Ba Y, Li N, Zhang R, Zhang J, Chen Y, Chen J, Huang M, Fu Y, Liu M, Liu Z, Zhao J, Li W, Wei J, Li C, Xu N, Guo Z, Cao B, Liu L, Nie P, Wan L, Sheng L, Liu Z, He Y, Gu K, Wu G, Wang W, Zhang F, Qiu W, Guo J, Ying J, Pan H, Xu H, Yuan Y, Bai Y, Wang Z, Xu J, Zhao X, Liu H, Zhang X, Dai W, Xu H, Liu M, Xie L, Tang Y, Jin J, Qu X, Fang X, Huang M, Chen H, Zheng Z, Wang Y, Wang D, Li X, Yu G, Liu H, Zhou Y, Zhong D, Zeng S, Kang M, Wang M, Gao Y, Li W, Wang Z, Zhang M, Zhang J, Li Q, Sun S, Zang A, Lin L, Xie M, Zhuang Z, Zhang T, Yao Z, Lu D, Liu W, Hu M, Wang ZM, Li B, Xia M, Zhang J, Ying X, Pardoll DM, Ji J. First-line cadonilimab plus chemotherapy in HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma: a randomized, double-blind, phase 3 trial. Nat Med. 2025 Jan 22. doi: 10.1038/s41591-024-03450-4. Epub ahead of print. PMID: 39843940.
Related Posts
Abbas N, Budoff M, Lakshmanan S. Imaging Inflammation: Epicardial Fat Density as an Imaging Marker of Cardiovascular Risk. Heart Int. 2025 Nov 24;19(2):29-34. doi: 10.17925/HI.2025.19.2.4.[...]
Chang AY, Johnson EK, Bolongaita S, Buse K, Hawkes SJ, Karlsson O, Knaul FM, Kruk ME, Norheim OF, Ogbuoji O, Watkins D, Jamison DT. From[...]
Babalyan V, Hutchings N, Baghdasaryan S, Qefoyan M, Kara-Poghosyan S, Nannipieri F, Battaglia S, Solfanelli L, Varzhapetyan A, Dallakyan G, Bilezikian JP. Kinetics and concentrations[...]
